Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butylphthalide is a synthetic compound derived from the seeds of Apium graveolens (Chinese celery) that has been approved in China for the treatment of ischemic stroke. It exists as a racemic mixture (dl-3-n-butylphthalide) in its therapeutic form. It functions as a neuroprotective agent with multiple mechanisms of action, including improving microcirculation, protecting mitochondrial function, inhibiting oxidative stress, inhibiting neuronal apoptosis, and anti-thrombotic effects. It was approved in China in 2002 for the treatment of ischemic stroke and has shown potential therapeutic effects in various neurological and non-neurological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butylphthalide.